Year All News2024202320222021 Mar 24 2022 MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa with HiSCR75 as the primary endpoint Read More + Oct 4 2021 MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody® Sonelokimab Read More + Aug 10 2021 MoonLake Immunotherapeutics appoints former Kymab CEO Simon Sturge as Chairman and Spike Loy to the Board of Directors Read More + Jul 1 2021 MoonLake Immunotherapeutics appoints Jorge Santos da Silva as CEO and Matthias Bodenstedt as CFO Read More + May 6 2021 MoonLake Immunotherapeutics announces publication in The Lancet Read More + May 3 2021 MoonLake In-licensing and launch Read More + Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Displaying 31 - 36 of 36
Mar 24 2022 MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa with HiSCR75 as the primary endpoint Read More +
Oct 4 2021 MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody® Sonelokimab Read More +
Aug 10 2021 MoonLake Immunotherapeutics appoints former Kymab CEO Simon Sturge as Chairman and Spike Loy to the Board of Directors Read More +
Jul 1 2021 MoonLake Immunotherapeutics appoints Jorge Santos da Silva as CEO and Matthias Bodenstedt as CFO Read More +